PAICS antibody
- Known as:
- PAICS (anti-)
- Catalog number:
- orb101759
- Product Quantity:
- 200 ug
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- PAICS antibody
Related genes to: PAICS antibody
- Gene:
- PAICS NIH gene
- Name:
- phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase
- Previous symbol:
- PAIS
- Synonyms:
- ADE2H1, AIRC
- Chromosome:
- 4q12
- Locus Type:
- gene with protein product
- Date approved:
- 1991-03-11
- Date modifiied:
- 2016-10-13
Related products to: PAICS antibody
Related articles to: PAICS antibody
- The effect of AI-assisted diagnosis on sonographer performance in real-world prenatal settings remains unclear. This study aimed to assess the Prenatal Ultrasound Diagnosis Artificial Intelligence Conduct System (PAICS) in detecting AI-recognisable intracranial malformations and its effect on identifying anomalies beyond its recognition scope in high-risk pregnancies. - Source: PubMed
Publication date: 2026/09/10
Lei TingShang NingXie BaiHongLuo YingChunZheng HongYuLi HeZhouZhang ChaoXueWang NanZhou QianXie HongNing - Non-small cell lung cancer (NSCLC) remains one of the leading causes of cancer-related mortality worldwide, highlighting the urgent need for effective therapeutic agents. Natural products represent an important source of novel anticancer compounds. In this study, we investigated the anti-NSCLC activity of 10,11-dehydrocurvularin (DCV), a fungal-derived macrolide. DCV potently inhibited the proliferation of NSCLC cell lines (A549 and NCI-H1703) in a dose-dependent manner, with IC₅₀ values of 7.92 μM and 5.33 μM, respectively. Furthermore, DCV (30 mg/kg) markedly suppressed tumor growth in A549 xenograft models without causing evident systemic toxicity, as evidenced by reduced tumor volume and weight, with no significant changes in body weight or organ histopathology. Through RNA-seq, drug affinity responsive target stability, and molecular docking analyses, we identified phosphoribosylaminoimidazole succinocarboxamide synthetase (PAICS), a key enzyme in de novo purine biosynthesis, as a direct binding target of DCV. Mechanistically, DCV engagement promoted PAICS protein downregulation and disrupted nucleotide metabolism, leading sequentially to mitochondrial dysfunction, reactive oxygen species accumulation, DNA damage, and cell cycle arrest, ultimately triggering intrinsic apoptosis. Collectively, these findings uncover the anti-NSCLC efficacy and mechanism of DCV, positioning it as a promising natural bioactive lead for subsequent pharmacological development against lung cancer. - Source: PubMed
Publication date: 2026/08/13
Wang YueChen SiyuHuang PingRehmutulla MewludeXiao YangDuan YaxinFu YangXia XianWei JiangchunHu ZhengxiTong QingyiZhang Yonghui - Parametric G-computation can align population-adjusted indirect comparisons (PAICs) with marginal estimands, but estimates may depend on unverifiable outcome-model specification. We evaluated Super Learner G-computation as a flexible outcome-modeling extension for anchored PAICs. - Source: PubMed
Publication date: 2026/08/18
Chen YingBao YunChen YuetingJin YanYao KaijieLi WenZhong YanWu Bin - Biallelic variants in PAICS, one of the 10 genes involved in the de novo purine synthesis (DNPS), were originally associated with an extremely rare phenotype characterized by multiple and severe congenital abnormalities, such as polyhydramnios due to esophageal atresia, congenital heart disease, and urogenital anomalies, which were lethal within the first days of life. Vertebral and limb defects, as well as distinctive craniofacial features, were also described. To date, three patients with these clinical characteristics but without neurologic involvement have been described in the literature. More recently, two siblings with none of these features but presenting a severe neurodevelopmental phenotype with regression and ocular involvement have been reported. We describe a new patient with two compound heterozygous variants in the PAICS gene, p.Ser35Phe and p.Cys281Ter, born with multiple congenital malformations overlapping those reported in the originally described patients: esophageal atresia, lung hypoplasia, vertebral anomalies, cryptorchidism, short stature, and dysmorphic facial features. He also had developmental delay; however, epilepsy did not occur. The features presented by our patient and the relatively longer follow up allowed us to detect in a single patient almost all the features previously described in different families. - Source: PubMed
Publication date: 2026/08/08
Monti LuigiIsidori FedericaCapriotti EmidioMinicucci AndreinaMichelangelo BaldazziDi Mitri MarcoScarano EmanuelaLima MarioPippucci TommasoSeveri Giulia - Lung adenocarcinoma (LUAD) is the most common type of lung cancer, often diagnosed in the advanced stage of diffuse metastasis, highly aggressive and rapidly fatal, lacking early diagnostic markers and effective therapeutic targets. Enzyme phosphoribosylaminoimidazole carboxylase/phosphoribosylaminoimidazole succinocarboxamide synthetase (PAICS) is an important bifunctional enzyme in purine de novo synthesis, and rapidly dividing cancer cells are heavily dependent on de novo synthesis of the adenine and guanine pathways. PAICS has been found to be highly expressed in a variety of cancers and has been shown to promote cancer proliferation or metastasis. However, the specific mechanism of action of PAICS in LUAD is unknown. Our study revealed that PAICS mRNA and protein levels were significantly increased in LUAD tumor tissues compared to adjacent normal tissues. Bioinformatics analysis showed that high PAICS expression was associated with LUAD metastasis and could be used as a factor for diagnosis and assessment of prognosis in LUAD patients. PAICS knockdown suppressed tumor cell migration and invasion, whereas overexpression enhanced these phenotypes. Mechanistically, PAICS promotes tumor metastasis by activating the Focal Adhesion Kinase (FAK) signaling through regulating the expression of Integrin α10 (ITGA10). FAK inhibitor Defactinib (VS6063) successfully inhibited PAICS overexpression-induced lung metastasis in vivo. In addition, we found that the high expression of PAICS in LUAD was regulated by mA modification. METTL3 (Methyltransferase-like 3) enhances the modification level of PAICS mRNA and IGF2BP2 (Insulin-like growth factor 2 mRNA binding protein 2) binds to its mRNA upon recognition of the mA modification site, which increased the stability of the mRNA and the expression. These results provide valuable insights into the biological functions of PAICS and potential avenues for new therapeutic approaches. - Source: PubMed
Publication date: 2026/07/23
Zhang MengzhuZhu JianjieZhang HuilingZhang JianshengZhao JianChen QiongjuZeng YuanyuanLi JianjunHuang Jian-AnLiu Zeyi